RxDoctor Payments Data

Satinder Aggarwal, MD

Internal Medicine · Taylor, MINPI 1700862034

Payments from drug & device makers

$8,476in general payments, 2019–2025

Across 548 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$994
  • AbbVie$916
  • Novo Nordisk$764
  • Amgen$659
  • Lilly USA, LLC$548
  • Pfizer$421
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,446100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,476 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$184,956
Medicare patients
174
Services billed
2,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$111,061
TrulicityDulaglutide65$75,060
FarxigaDapagliflozin Propanediol99$71,229
JardianceEmpagliflozin91$69,180
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$55,051
EliquisApixaban49$41,240
MounjaroTirzepatide28$31,848
EntrestoSacubitril/Valsartan25$28,993
ArexvyRsvpref3 Antigen/As01e/Pf95$27,922
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$21,202
LinzessLinaclotide34$20,889
XareltoRivaroxaban30$17,554
Breo ElliptaFluticasone/Vilanterol38$16,958
JanuviaSitagliptin Phosphate19$13,687
ShingrixVaricella-Zoster Ge/As01b/Pf64$13,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$764$124,184124 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$341$113,351278 claims
Lilly USA, LLCTrulicity, Mounjaro$548$106,90893 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$994$99,446152 claims
Boehringer IngelheimJardiance$59$69,18091 claims
PfizerEliquis$421$41,24049 claims
NovartisEntresto$367$28,99325 claims
AbbVieLinzess$916$20,88934 claims
Johnson & JohnsonXarelto$46$17,55430 claims
MerckJanuvia$327$13,68719 claims
Astellas Pharma US IncMyrbetriq$64$9,93819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Taylor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →